Atrys Health SA · BME:ATRY
Atrys Health SA — H1 2023 Earnings Presentation
23 slides from Atrys Health SA's earnings presentation, Sep 29, 2023
Slide 1: Presentation of 1H 2023 results
29 September 2023 Presentation of 1H 2023 results
Slide 2: Warning / Disclaimer and Cautionary Statements
Warning / Disclaimer and Cautionary Statements This document and the results conference call (including the The forward-looking statements or forecasts contained in this Except to the extent required by applicable law, ATRYS question and answer session) may contain forward-looking document may be id
Slide 3: Guidance 2023
Guidance 2023 Not incorporating acquisitions or divestments of assets Turnover evolution Adjusted EBITDA evolution EUR mn EUR mn 232-238 187 121 118,2 52-53 41,3 25,7 25,7 11 20,8 7,0 13 7,3 3,3 2018 2019 2020 2021 2022 2023 1H2023 2018 2019 2020 2021 2022 2023 1H2023 Guidance Guidance
Slide 4: Atrys, 360º Health Services
Atrys, 360º Health Services We are a global provider of healthcare services. We bring to any part of the world a comprehensive healthcare service that offers innovative healthcare solutions customised for each patient. Compliance BUSINESS oncology AREAS Health surveillance and screening High-precisi
Slide 5: Business areas: Oncology
Business areas: Oncology Business model Patient Insurance companies / Medical and Radiation Health centres Oncology Centres Integration of Initia (Oncology and Research), acquired in December 2022, at operational, commercial and financial level. Boosting clinical trial activity in MO. Medical Oncolo
Slide 6: Business areas: Diagnostics
Business areas: Diagnostics Business model Patient Insurance Health Centre Telemedicine / company Telediagnosis Opening of a pathology laboratory in Madrid equipped with state of the art Results Results technologies and contract with Sanitas. Market leader in pathology in Spain. Labs / Med. Nuclear
Slide 7: Business areas: Preventive medicine
Business areas: Preventive medicine Business model Employees Company Health Surveillance Service / Improved productivity and efficiency. -> Improve margins: Technical Prevention Service - Optimisation of the network of centres. - Increase in production units (5 new units). - 13% improvement in produ
Slide 8: Key figures for H1
Key figures for H1 2023 We confirm the organic growth guidance for the financial year 2023. NIIF UE chg (%) ('000 EUR) 1H 2022 1H 2023 0 Turnover 88.911 118.236 33,0% Turnover growth of +33% to €118.2M (+9% like for like and +10.3% ex COVID-related revenues). Gross Margin (APM) 74.697 86.215 15,4% %
Slide 9: Key figures for H1 2023
Key figures for H1 2023 Proforma Turnover(1) by segment ' Like for like' turnover development ('000 EUR) 1H 2022 1H 2023 chg (%) 1) Precision Medicine 52.356 60.089 14,8% 1.1) Oncology 25.915 28.251 9,0% 2.2) Diagnostics 26.441 31.838 20,4% 2) Preventive Medicine 39.652 42.556 7,3% 3) Compliance ser
Slide 10: Key figures for H1 2023: Gross margin development
Key figures for H1 2023 Gross margin development 84,0% -6,2% 77,8% -2,95% -2,0% 75,0% 72,8% The Prevention and Compliance segments with annual tariff renewals in the contracts at the beginning of the year maintain their gross margins. In Precision Medicine, tariff updates occur when contracts are re
Slide 11: Key figures for H1 2023: Bridge extraordinary impacts
Key figures for H1 2023 Bridge extraordinary impacts on consolidated result H1 2023 (figures in thousands of EUR) Impacts on the first half-year result 2023 3.084 4.220 1.138 9.940 8.100 6.100 01 Non-recurring expenses 1H23 correspond mainly to the optimisation of the personnel structure (severance
Slide 12: Key figures H1 2023: Financial debt position
Key figures H1 2023 Financial debt position Financial structure as of June 2023: Debt repayment schedule: (figures in thousands of EUR) Net leverage 180 ratio1 : 4.46x TLB + Bank Debt: 154.8M EUR 33 3 4 9 2 Public Debt R&D: 6,6M EUR MARF Bond + Jun/2024 Jun/2025 Jun/2026 Jun/2027 Jun/2028 >jun/2029
Slide 13: The action
The action Analyst Target Prices : Shareholder composition: Target 30/06/2023 8,1% Date Price Management 6,4 Kepler 07/23 Team 33,4% ODDO 22/06 6,5 Free Float Alantra 03/23 7,2 - 9,2 24,7% 8,57 GPM 04/23 Excelsior Times GVC Gaesco 09/23 9,5 Renta 4 01/23 8,7 7,3% JB Capital Markets 03/23 7,7 Venture
Slide 14: ESG
ESG Clarity AI Industry Consensus ESG Score Atrys achieves an ESG score by Clarity AI of 64 out of 100 in September 2023: - With this score, Atrys is positioned in the 89th percentile out of a universe of 100 companies in the Health Services Sector analyzed by Clarity AI. - Atrys is above average an
Slide 15: Trajectory
Trajectory Trajectory In the last 5 years ATRYS has established itself as a global consolidator by aggregating 17 companies to lead the precision Guidance 2023 Organic 232-235 CAGR (%) 2016-2022 medicine and prevention segments. PROFORMA REVENUES +89.9% #1 Spanish-language B2B tele-diagnostic compan
Slide 16: Thank you!
fo ‘L <> atrys Thankyou!
Slide 17: Annex I: Consolidated P&L
Annex I june 30th 2023 Consolidated P&L (000 EUR) 1H 2022 2022/23 chg (%) Net Turnover 88.911 118.236 33,0% Other operating income 367 148 -59,7% Work carried out by the group for its assets 1.588 2.079 30,9% Purchases (14.214) (32.021) 125,3% Employee expenses (43.262) (50.568) 16,9% Other operatin
Slide 18: Annex I: Consolidated Balance Sheet
Annex I Consolidated Balance Sheet ASSETS EQUITY & LIABILITIES june 30th june 30th ('000 EUR) 31/12/2022 1H 2023 chg (%) ('00 EUR) 31/12/2022 1H 2023 chg (%) NON-CURRENT ASSETS 602.176 588.174 -2,3% NET EQUITY 337.573 317.890 -5,8% Intangible assets 518.902 504.173 -2,8% NON-CURRENT LIABILITIES 267.
Slide 19: Annex I: P&L by business segment H1 2023
Annex I PYG by business segment as of Business Segments H1 2023 june 30th 2023 Precision Preventive Compliance ('000 EUR) Medicine Medicine Services Corporate Total Net Turnover 59.723 42.556 15.957 0 118.236 Spain 36.118 42.556 15.957 0 94.631 Portugal 6.132 0 0 0 6.132 Latam 17.473 0 0 0 17.473 Pu
Slide 20: Annex I: P&L by business segment H1 2022
Annex I PYG by business segment as of Business Segments H1 2022 june 30th 2022 ('000 EUR) Precision Medicine Preventive Medicine Compliance Services Corporate Total Net Turnover 33.182 40.206 15.523 0 88.911 Spain 13.038 40.206 15.523 0 68.767 Portugal 7.236 0 0 0 7.236 Latam 12.908 0 0 0 12.908 Pur
Slide 21: Annex I: Reconciliation of Proforma data
Annex I Reconciliation of Proforma data to First Half 2023 and first half 2022
Slide 22: Annex II: Alternative Performance Definitions (MAR)
Annex II As well as the amount of incentive plans for the Group's Alternative Average Performance Definitions (MAR) management team recognised in an expense account that do not result in a cash outflow. GROSS MARGIN (MAR) Gross Margin(MAR) corresponds to net sales less supplies. In addition, it will
Slide 23: Annex II: Alternative Performance Definitions (MAR)
Annex II Alternative Average Performance Definitions (MAR) OPERATING CASH FLOW (MAR) Operating cash flow(MAR) means EBITDA(MAR) for the period minus CAPEX(MAR) and CAPEX R&D(MAR) . ADJUSTED OPERATING CASH Adjusted operating cash flow(MAR) means adjusted EBITDA(MAR) for the period minus CAPEX (MAR) a